Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BridgeBio Oncology Therapeutics, Inc.BBOT · Entity 5215 | Director | June 16, 2026 | June 18, 2026 |
| BridgeBio Pharma, Inc.BBIO · Entity 3360 | Director · Chief Executive Officer | September 17, 2026 | September 21, 2026 |
| Eidos Therapeutics, Inc.EIDX · Entity 143355 | Director · Chief Executive Officer · 10% owner | July 03, 2019 | July 09, 2019 |
| LianBioLIAN · Entity 9881 | Director | October 29, 2021 | November 09, 2021 |
| Maze Therapeutics, Inc.MAZE · Entity 1775 | Director | March 27, 2026 | March 31, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BridgeBio Oncology Therapeutics, Inc.
Report date June 16, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.73 · Expires 2036-06-15 | Direct | 31,675 |
Reported balance
After 2026-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 31,675 · Balance 31,675 F1: The shares underlying the stock option vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting of Stockholders of the Issuer following the date of grant, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the stock option vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting of Stockholders of the Issuer following the date of grant, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.
BridgeBio Pharma, Inc.
Report date September 17, 2026 · Filed September 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. | 495,686 |
Last balance in matching sequence
After 2026-09-17 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-09-17 · Sale · Disposed 8,721 · Balance 496,965 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026. F2: Represents the weighted average sale price of the shares sold from $68.52 to $69.40 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Row 2 · 2026-09-17 · Sale · Disposed 1,279 · Balance 495,686 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026. F4: Represents the weighted average sale price of the shares sold from $69.525 to $69.64 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. | 3,568,447 |
Reported balance
Holding disclosure · report date 2026-09-17 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 3,568,447 F3: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy NK 2026 GRAT | 750,000 |
Reported balance
Holding disclosure · report date 2026-09-17 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 750,000 F5: These shares are held by the NK 2026 GRAT, a grantor retained annuity trust of which the Reporting Person is the sole trustee and sole annuitant. The Reporting Person disclaims beneficial ownership of the shares held by the NK 2026 GRAT except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 243,327 |
Reported balance
Holding disclosure · report date 2026-09-17 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 243,327 |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026.
F2: Represents the weighted average sale price of the shares sold from $68.52 to $69.40 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
F3: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
F4: Represents the weighted average sale price of the shares sold from $69.525 to $69.64 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
F5: These shares are held by the NK 2026 GRAT, a grantor retained annuity trust of which the Reporting Person is the sole trustee and sole annuitant. The Reporting Person disclaims beneficial ownership of the shares held by the NK 2026 GRAT except to the extent of his pecuniary interest therein.
Eidos Therapeutics, Inc.
Report date July 03, 2019 · Filed July 09, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 24,575,501 |
Reported balance
After 2019-07-03 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2019-07-03 · Purchase · Acquired 882,353 · Balance 24,575,501 F1: The shares are owned by BridgeBio Pharma LLC. The Reporting Person is the chief executive officer and a member of the board of managers of BridgeBio Pharma LLC and may be deemed to beneficially own the shares held by BridgeBio Pharma LLC. The Reporting Person disclaims beneficial ownership of the shares for Section 16 purposes or for any other purpose, except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares are owned by BridgeBio Pharma LLC. The Reporting Person is the chief executive officer and a member of the board of managers of BridgeBio Pharma LLC and may be deemed to beneficially own the shares held by BridgeBio Pharma LLC. The Reporting Person disclaims beneficial ownership of the shares for Section 16 purposes or for any other purpose, except to the extent of his pecuniary interest therein.
LianBio
Report date October 29, 2021 · Filed November 09, 2021 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | IndirectBy BridgeBio Pharma LLC | 5,002,792 |
Reported balance
Holding disclosure · report date 2021-10-29 · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · Balance 5,002,792 F1: The shares are held by BridgeBio Pharma LLC, a wholly-owned subsidiary of BridgeBio Pharma, Inc. Dr. Neil Kumar is the President and Chief Executive Officer and a director of BridgeBio Pharma, Inc., and as a result may be deemed to share voting and investing power over these Ordinary Shares. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares are held by BridgeBio Pharma LLC, a wholly-owned subsidiary of BridgeBio Pharma, Inc. Dr. Neil Kumar is the President and Chief Executive Officer and a director of BridgeBio Pharma, Inc., and as a result may be deemed to share voting and investing power over these Ordinary Shares. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Maze Therapeutics, Inc.
Report date March 27, 2026 · Filed March 31, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.38 · Expires 2036-03-26 | Direct | 33,417 |
Reported balance
After 2026-03-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-27 · Grant · Acquired 33,417 · Balance 33,417 F1: The option shall vest as to 1/36th of the total award monthly, with the first tranche vesting on April 27, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest as to 1/36th of the total award monthly, with the first tranche vesting on April 27, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 17, 2026 Filed Sep 21, 2026 22:21 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 1,279 | $69.57 | $88,979.52 |
DisclosureSEC source: 0001470831-26-000897 · wk-form4_1790029286.xml · nonDerivative · entry 2 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 495,686 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026. F4 · price: Represents the weighted average sale price of the shares sold from $69.525 to $69.64 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| September 17, 2026 Filed Sep 21, 2026 22:21 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 8,721 | $69.01 | $601,867.61 |
DisclosureSEC source: 0001470831-26-000897 · wk-form4_1790029286.xml · nonDerivative · entry 1 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 496,965 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026. F2 · price: Represents the weighted average sale price of the shares sold from $68.52 to $69.40 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| August 19, 2026 Filed Aug 20, 2026 20:31 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 100 | $85.65 | $8,565.00 |
DisclosureSEC source: 0001470831-26-000848 · wk-form4_1787257884.xml · nonDerivative · entry 7 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 505,686 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026. F7 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| August 19, 2026 Filed Aug 20, 2026 20:31 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 1,800 | $84.69 | $152,436.06 |
DisclosureSEC source: 0001470831-26-000848 · wk-form4_1787257884.xml · nonDerivative · entry 6 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 505,786 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026. F8 · price: Represents the weighted average sale price of the shares sold from $84.35 to $85.21 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F7 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| August 19, 2026 Filed Aug 20, 2026 20:31 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 8,100 | $83.86 | $679,256.28 |
DisclosureSEC source: 0001470831-26-000848 · wk-form4_1787257884.xml · nonDerivative · entry 5 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 507,586 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026. F6 · price: Represents the weighted average sale price of the shares sold from $83.34 to $84.31 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F7 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| August 18, 2026 Filed Aug 20, 2026 20:31 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 1,199 | $83.77 | $100,444.07 |
DisclosureSEC source: 0001470831-26-000848 · wk-form4_1787257884.xml · nonDerivative · entry 4 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 243,327 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026. F5 · price: Represents the weighted average sale price of the shares sold from $83.65 to $83.90 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document |
| August 18, 2026 Filed Aug 20, 2026 20:31 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 14,602 | $82.99 | $1,211,852.10 |
DisclosureSEC source: 0001470831-26-000848 · wk-form4_1787257884.xml · nonDerivative · entry 3 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 244,526 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026. F4 · price: Represents the weighted average sale price of the shares sold from $82.62 to $83.61 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document |
| August 18, 2026 Filed Aug 20, 2026 20:31 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 17,279 | $82.21 | $1,420,513.50 |
DisclosureSEC source: 0001470831-26-000848 · wk-form4_1787257884.xml · nonDerivative · entry 2 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 259,128 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026. F3 · price: Represents the weighted average sale price of the shares sold from $81.62 to $82.61 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document |
| August 18, 2026 Filed Aug 20, 2026 20:31 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 1,900 | $81.15 | $154,183.86 |
DisclosureSEC source: 0001470831-26-000848 · wk-form4_1787257884.xml · nonDerivative · entry 1 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 276,407 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026. F2 · price: Represents the weighted average sale price of the shares sold from $80.54 to $81.53 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document |
| August 16, 2026 Filed Aug 18, 2026 22:02 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 6,520 | $0.00 | $0.00 |
DisclosureSEC source: 0001470831-26-000836 · wk-form4_1787090549.xml · derivative · entry 12 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,274 Underlying: Common Stock · 6,520 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F9 · derivative.exercise_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2026. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F9 · derivative.expiration_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2026. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| August 16, 2026 Filed Aug 18, 2026 22:02 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 11,554 | $0.00 | $0.00 |
DisclosureSEC source: 0001470831-26-000836 · wk-form4_1787090549.xml · derivative · entry 11 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,538 Underlying: Common Stock · 11,554 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F8 · derivative.exercise_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2025. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F8 · derivative.expiration_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2025. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| August 16, 2026 Filed Aug 18, 2026 22:02 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 19,599 | $0.00 | $0.00 |
DisclosureSEC source: 0001470831-26-000836 · wk-form4_1787090549.xml · derivative · entry 10 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,596 Underlying: Common Stock · 19,599 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F7 · derivative.exercise_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F7 · derivative.expiration_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| August 16, 2026 Filed Aug 18, 2026 22:02 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 33,544 | $0.00 | $0.00 |
DisclosureSEC source: 0001470831-26-000836 · wk-form4_1787090549.xml · derivative · entry 9 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,088 Underlying: Common Stock · 33,544 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F6 · derivative.exercise_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F6 · derivative.expiration_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| August 16, 2026 Filed Aug 18, 2026 22:02 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 36,237 | $79.86 | $2,893,886.82 |
DisclosureSEC source: 0001470831-26-000836 · wk-form4_1787090549.xml · nonDerivative · entry 5 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 278,307 F2 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 71,217 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| August 16, 2026 Filed Aug 18, 2026 22:02 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 6,520 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001470831-26-000836 · wk-form4_1787090549.xml · nonDerivative · entry 4 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 314,544 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| August 16, 2026 Filed Aug 18, 2026 22:02 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 11,554 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001470831-26-000836 · wk-form4_1787090549.xml · nonDerivative · entry 3 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 308,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| August 16, 2026 Filed Aug 18, 2026 22:02 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 19,599 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001470831-26-000836 · wk-form4_1787090549.xml · nonDerivative · entry 2 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 296,470 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| August 16, 2026 Filed Aug 18, 2026 22:02 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 33,544 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001470831-26-000836 · wk-form4_1787090549.xml · nonDerivative · entry 1 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 276,871 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| June 16, 2026 Filed Jun 18, 2026 20:53 UTC | BridgeBio Oncology Therapeutics, Inc. BBOT · Entity 5215 | GrantStock Option (Right to Buy) · Derivative | 31,675 | $0.00 Strike: $7.73 | $0.00 |
DisclosureSEC source: 0001193125-26-276033 · ownership.xml · derivative · entry 1 Kumar Neil · CIK 0001742485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,675 Underlying: Common Stock · 31,675 shares Expires 2036-06-15 F1 · derivative.exercise_date: The shares underlying the stock option vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting of Stockholders of the Issuer following the date of grant, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. Read SEC document |
| June 05, 2026 Filed Jun 8, 2026 22:01 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 4,415 | $68.96 | $304,455.31 |
DisclosureSEC source: 0001470831-26-000523 · wk-form4_1780956089.xml · nonDerivative · entry 14 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 4,318,447 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F9 · price: Represents the weighted average sale price of the shares sold from $68.61 to $69.51 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| June 05, 2026 Filed Jun 8, 2026 22:01 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 8,437 | $67.88 | $572,744.06 |
DisclosureSEC source: 0001470831-26-000523 · wk-form4_1780956089.xml · nonDerivative · entry 13 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 4,322,862 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F8 · price: Represents the weighted average sale price of the shares sold from $67.61 to $68.605 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| June 05, 2026 Filed Jun 8, 2026 22:01 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 7,148 | $67.20 | $480,338.45 |
DisclosureSEC source: 0001470831-26-000523 · wk-form4_1780956089.xml · nonDerivative · entry 12 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 4,331,299 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F7 · price: Represents the weighted average sale price of the shares sold from $66.59 to $67.58 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| June 05, 2026 Filed Jun 8, 2026 22:01 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 4,416 | $68.96 | $304,524.27 |
DisclosureSEC source: 0001470831-26-000523 · wk-form4_1780956089.xml · nonDerivative · entry 11 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 515,686 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F9 · price: Represents the weighted average sale price of the shares sold from $68.61 to $69.51 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| June 05, 2026 Filed Jun 8, 2026 22:01 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 8,437 | $67.88 | $572,744.06 |
DisclosureSEC source: 0001470831-26-000523 · wk-form4_1780956089.xml · nonDerivative · entry 10 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 520,102 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F8 · price: Represents the weighted average sale price of the shares sold from $67.61 to $68.605 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| June 05, 2026 Filed Jun 8, 2026 22:01 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 7,147 | $67.20 | $480,271.25 |
DisclosureSEC source: 0001470831-26-000523 · wk-form4_1780956089.xml · nonDerivative · entry 9 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 528,539 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F7 · price: Represents the weighted average sale price of the shares sold from $66.59 to $67.58 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| June 04, 2026 Filed Jun 8, 2026 22:01 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 450 | $68.27 | $30,721.37 |
DisclosureSEC source: 0001470831-26-000523 · wk-form4_1780956089.xml · nonDerivative · entry 8 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 4,338,447 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F6 · price: Represents the weighted average sale price of the shares sold from $68.17 to $68.38 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| June 04, 2026 Filed Jun 8, 2026 22:01 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 15,921 | $67.74 | $1,078,451.92 |
DisclosureSEC source: 0001470831-26-000523 · wk-form4_1780956089.xml · nonDerivative · entry 7 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 4,338,897 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F5 · price: Represents the weighted average sale price of the shares sold from $67.17 to $68.16 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| June 04, 2026 Filed Jun 8, 2026 22:01 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 1,429 | $66.72 | $95,347.17 |
DisclosureSEC source: 0001470831-26-000523 · wk-form4_1780956089.xml · nonDerivative · entry 6 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 4,354,818 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F4 · price: Represents the weighted average sale price of the shares sold from $66.15 to $67.14 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| June 04, 2026 Filed Jun 8, 2026 22:01 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 2,200 | $65.72 | $144,584.44 |
DisclosureSEC source: 0001470831-26-000523 · wk-form4_1780956089.xml · nonDerivative · entry 5 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 4,356,247 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F2 · price: Represents the weighted average sale price of the shares sold from $65.145 to $66.12 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| June 04, 2026 Filed Jun 8, 2026 22:01 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 450 | $68.27 | $30,721.37 |
DisclosureSEC source: 0001470831-26-000523 · wk-form4_1780956089.xml · nonDerivative · entry 4 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 535,686 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F6 · price: Represents the weighted average sale price of the shares sold from $68.17 to $68.38 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| June 04, 2026 Filed Jun 8, 2026 22:01 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 15,921 | $67.74 | $1,078,453.51 |
DisclosureSEC source: 0001470831-26-000523 · wk-form4_1780956089.xml · nonDerivative · entry 3 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 536,136 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F5 · price: Represents the weighted average sale price of the shares sold from $67.17 to $68.16 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| June 04, 2026 Filed Jun 8, 2026 22:01 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 1,429 | $66.72 | $95,347.17 |
DisclosureSEC source: 0001470831-26-000523 · wk-form4_1780956089.xml · nonDerivative · entry 2 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 552,057 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F4 · price: Represents the weighted average sale price of the shares sold from $66.15 to $67.14 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| June 04, 2026 Filed Jun 8, 2026 22:01 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 2,200 | $65.72 | $144,584.44 |
DisclosureSEC source: 0001470831-26-000523 · wk-form4_1780956089.xml · nonDerivative · entry 1 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 553,486 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F2 · price: Represents the weighted average sale price of the shares sold from $65.145 to $66.12 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| May 21, 2026 Filed May 26, 2026 20:54 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 800 | $70.92 | $56,735.12 |
DisclosureSEC source: 0001470831-26-000488 · wk-form4_1779828852.xml · nonDerivative · entry 5 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 243,327 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F6 · price: Represents the weighted average sale price of the shares sold from $70.86 to $70.97 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document |
| May 21, 2026 Filed May 26, 2026 20:54 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 11,250 | $70.48 | $792,915.75 |
DisclosureSEC source: 0001470831-26-000488 · wk-form4_1779828852.xml · nonDerivative · entry 4 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 244,127 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F5 · price: Represents the weighted average sale price of the shares sold from $69.86 to $70.85 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document |
| May 21, 2026 Filed May 26, 2026 20:54 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 5,072 | $69.22 | $351,101.59 |
DisclosureSEC source: 0001470831-26-000488 · wk-form4_1779828852.xml · nonDerivative · entry 3 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 255,377 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F4 · price: Represents the weighted average sale price of the shares sold from $68.81 to $69.78 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document |
| May 21, 2026 Filed May 26, 2026 20:54 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 6,725 | $68.30 | $459,334.31 |
DisclosureSEC source: 0001470831-26-000488 · wk-form4_1779828852.xml · nonDerivative · entry 2 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 260,449 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F3 · price: Represents the weighted average sale price of the shares sold from $67.81 to $68.80 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document |
| May 21, 2026 Filed May 26, 2026 20:54 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 2,256 | $67.57 | $152,434.99 |
DisclosureSEC source: 0001470831-26-000488 · wk-form4_1779828852.xml · nonDerivative · entry 1 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 267,174 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F2 · price: Represents the weighted average sale price of the shares sold from $66.81 to $67.80 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document |
| May 16, 2026 Filed May 19, 2026 20:27 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 6,519 | $0.00 | $0.00 |
DisclosureSEC source: 0001470831-26-000472 · wk-form4_1779222471.xml · derivative · entry 11 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,794 Underlying: Common Stock · 6,519 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F7 · derivative.exercise_date: The RSUs will vest with respect to 1/16th of the underlying shares on May 16, 2026. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F7 · derivative.expiration_date: The RSUs will vest with respect to 1/16th of the underlying shares on May 16, 2026. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| May 16, 2026 Filed May 19, 2026 20:27 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 11,553 | $0.00 | $0.00 |
DisclosureSEC source: 0001470831-26-000472 · wk-form4_1779222471.xml · derivative · entry 10 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,092 Underlying: Common Stock · 11,553 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F6 · derivative.exercise_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2025. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F6 · derivative.expiration_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2025. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| May 16, 2026 Filed May 19, 2026 20:27 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 19,599 | $0.00 | $0.00 |
DisclosureSEC source: 0001470831-26-000472 · wk-form4_1779222471.xml · derivative · entry 9 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,195 Underlying: Common Stock · 19,599 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F5 · derivative.expiration_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| May 16, 2026 Filed May 19, 2026 20:27 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 33,544 | $0.00 | $0.00 |
DisclosureSEC source: 0001470831-26-000472 · wk-form4_1779222471.xml · derivative · entry 8 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,632 Underlying: Common Stock · 33,544 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F4 · derivative.expiration_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| May 16, 2026 Filed May 19, 2026 20:27 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 36,236 | $66.13 | $2,396,286.68 |
DisclosureSEC source: 0001470831-26-000472 · wk-form4_1779222471.xml · nonDerivative · entry 5 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 269,430 F2 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 71,215 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| May 16, 2026 Filed May 19, 2026 20:27 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 6,519 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001470831-26-000472 · wk-form4_1779222471.xml · nonDerivative · entry 4 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 305,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| May 16, 2026 Filed May 19, 2026 20:27 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 11,553 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001470831-26-000472 · wk-form4_1779222471.xml · nonDerivative · entry 3 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 299,147 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| May 16, 2026 Filed May 19, 2026 20:27 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 19,599 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001470831-26-000472 · wk-form4_1779222471.xml · nonDerivative · entry 2 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 287,594 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| May 16, 2026 Filed May 19, 2026 20:27 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 33,544 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001470831-26-000472 · wk-form4_1779222471.xml · nonDerivative · entry 1 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 267,995 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| May 08, 2026 Filed May 11, 2026 21:15 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 950 | $68.35 | $64,930.32 |
DisclosureSEC source: 0001470831-26-000423 · wk-form4_1778534126.xml · nonDerivative · entry 12 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 4,358,447 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F8 · price: Represents the weighted average sale price of the shares sold from $68.17 to $68.75 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| May 08, 2026 Filed May 11, 2026 21:15 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 5,076 | $67.35 | $341,845.76 |
DisclosureSEC source: 0001470831-26-000423 · wk-form4_1778534126.xml · nonDerivative · entry 11 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 4,359,397 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F7 · price: Represents the weighted average sale price of the shares sold from $67.10 to $68.07 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| May 08, 2026 Filed May 11, 2026 21:15 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 13,974 | $66.65 | $931,374.09 |
DisclosureSEC source: 0001470831-26-000423 · wk-form4_1778534126.xml · nonDerivative · entry 10 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 4,364,473 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F6 · price: Represents the weighted average sale price of the shares sold from $66.10 to $67.09 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.